<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND AND PURPOSE: We compared the activity of a new long-half-life, fibrin-specific tissue-type plasminogen activator (<z:chebi fb="6" ids="15702,53394">TPA</z:chebi>) variant with that of <z:mp ids='MP_0002169'>wild-type</z:mp> <z:chebi fb="6" ids="15702,53394">TPA</z:chebi> in rabbit models of embolic <z:hpo ids='HP_0001297'>stroke</z:hpo> and peripheral <z:mp ids='MP_0001914'>bleeding</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: In the embolic <z:hpo ids='HP_0001297'>stroke</z:hpo> model </plain></SENT>
<SENT sid="2" pm="."><plain><z:chebi fb="6" ids="15702,53394">TPA</z:chebi>-induced clot lysis is followed by continuous monitoring of a radiolabeled clot lodged in the middle cerebral artery </plain></SENT>
<SENT sid="3" pm="."><plain>Twenty-four hours after embolization and treatment with either thrombolytic agent or excipient, the brains are removed, fixed, and evaluated for <z:hpo ids='HP_0001342'>cerebral hemorrhage</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>In a parallel template <z:mp ids='MP_0001914'>bleeding</z:mp> time experiment, the effects of equipotent doses of the two <z:chebi fb="6" ids="15702,53394">TPA</z:chebi> molecules were measured </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: Infusion of <z:mp ids='MP_0002169'>wild-type</z:mp> <z:chebi fb="6" ids="15702,53394">TPA</z:chebi> or bolus administration of the <z:chebi fb="6" ids="15702,53394">TPA</z:chebi> variant resulted in dose-dependent clot lysis </plain></SENT>
<SENT sid="6" pm="."><plain>The <z:chebi fb="6" ids="15702,53394">TPA</z:chebi> variant was found to be an order of magnitude more potent than <z:mp ids='MP_0002169'>wild-type</z:mp> <z:chebi fb="6" ids="15702,53394">TPA</z:chebi> on a milligram-per-kilogram basis </plain></SENT>
<SENT sid="7" pm="."><plain>Unlike <z:mp ids='MP_0002169'>wild-type</z:mp> <z:chebi fb="6" ids="15702,53394">TPA</z:chebi>, the variant caused less systemic activation of plasminogen (P &lt; .05) and fewer hemorrhagic transformations in this model (P &lt; .05) </plain></SENT>
<SENT sid="8" pm="."><plain>The <z:chebi fb="6" ids="15702,53394">TPA</z:chebi> variant did not extend template <z:mp ids='MP_0001914'>bleeding</z:mp> times </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSIONS: These findings show that by combining increased fibrin specificity with decreased plasma clearance, it is possible to produce a thrombolytic agent that is more convenient and more potent than wild-tpe <z:chebi fb="6" ids="15702,53394">TPA</z:chebi> </plain></SENT>
<SENT sid="10" pm="."><plain>At the same time the significant reduction in hemorrhagic conversions may be attributable to the conservation of systemic plasminogen seen with this molecule </plain></SENT>
</text></document>